What is the market capitalization of Biomea Fusion, Inc.?

Biomea Fusion, Inc. (BMEA) has a market capitalization of approximately 93,989,272 USD.

How many ETFs hold BMEA?

BMEA is held by 3 ETFs tracked on Investir en Bourse.

Where can I buy BMEA in Canada?

BMEA can be purchased through any Canadian online broker including Wealthsimple, Questrade, Qtrade, or RBC Direct Investing.

BMEA

Biomea Fusion, Inc.

Biomea Fusion, Inc. (BMEA) is an American company in the healthcare sector, listed on NASDAQ. Market capitalization of 94 million USD (micro-cap).

Details

Price1.30 USD

Market cap93.99 M USD

Payout ratio0.00%

ROE-189.44%

Debt / Equity6.62%

SectorHealthcare

Websitebiomeafusion.com

Updated 1h ago

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.